Entellus Medical, Inc. (NASDAQ:ENTL) has been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $21.25.

Several equities research analysts have recently commented on ENTL shares. BidaskClub downgraded shares of Entellus Medical from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Piper Jaffray Companies reiterated a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Zacks Investment Research upgraded shares of Entellus Medical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Canaccord Genuity downgraded shares of Entellus Medical from a “buy” rating to a “hold” rating and reduced their price target for the stock from $22.00 to $18.00 in a research report on Thursday, May 4th. Finally, William Blair reiterated an “outperform” rating on shares of Entellus Medical in a research report on Wednesday, May 10th.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/08/15/entellus-medical-inc-entl-given-consensus-recommendation-of-hold-by-analysts.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after buying an additional 2,594 shares during the period. Nationwide Fund Advisors increased its position in shares of Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares during the period. First Mercantile Trust Co. increased its position in shares of Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after buying an additional 2,557 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after buying an additional 573 shares during the period. Finally, Kopp Investment Advisors LLC increased its position in shares of Entellus Medical by 0.5% in the second quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after buying an additional 55 shares during the period. Institutional investors and hedge funds own 67.61% of the company’s stock.

Entellus Medical (ENTL) opened at 16.86 on Tuesday. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $22.63. The firm’s 50-day moving average is $16.97 and its 200 day moving average is $14.92. The firm’s market cap is $427.76 million.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The firm had revenue of $22.10 million during the quarter, compared to analyst estimates of $21.87 million. During the same quarter in the prior year, the firm posted ($0.27) EPS. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, equities analysts forecast that Entellus Medical will post ($1.62) earnings per share for the current fiscal year.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.